Our results, therefore, indicate that CXCL13 neutralizing MAb 5261 antibody has potential for treatment of autoimmune disorders, including Multiple Sclerosis and Rheumatoid Arthritis. This evidence concerns the gene CXCL13 and multiple sclerosis.